These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 20170097

  • 1. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents.
    Li WT, Hwang DR, Song JS, Chen CP, Chuu JJ, Hu CB, Lin HL, Huang CL, Huang CY, Tseng HY, Lin CC, Chen TW, Lin CH, Wang HS, Shen CC, Chang CM, Chao YS, Chen CT.
    J Med Chem; 2010 Mar 25; 53(6):2409-17. PubMed ID: 20170097
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.
    Anticancer Res; 2004 Mar 25; 24(2B):907-19. PubMed ID: 15161044
    [Abstract] [Full Text] [Related]

  • 3. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 25; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 4. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM, Ladesich JB, Magill MJ, Chen Y, Hua DH, Perchellet JP.
    Anticancer Drugs; 1999 Jun 25; 10(5):489-504. PubMed ID: 10477169
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.
    Li WT, Hwang DR, Song JS, Chen CP, Chen TW, Lin CH, Chuu JJ, Lien TW, Hsu TA, Huang CL, Tseng HY, Lin CC, Lin HL, Chang CM, Chao YS, Chen CT.
    Invest New Drugs; 2012 Feb 25; 30(1):164-75. PubMed ID: 20890633
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
    Xue N, Yang X, Wu R, Chen J, He Q, Yang B, Lu X, Hu Y.
    Bioorg Med Chem; 2008 Mar 01; 16(5):2550-7. PubMed ID: 18226907
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents.
    Li WT, Hwang DR, Chen CP, Shen CW, Huang CL, Chen TW, Lin CH, Chang YL, Chang YY, Lo YK, Tseng HY, Lin CC, Song JS, Chen HC, Chen SJ, Wu SH, Chen CT.
    J Med Chem; 2003 Apr 24; 46(9):1706-15. PubMed ID: 12699388
    [Abstract] [Full Text] [Related]

  • 8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 9. BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
    Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Ho PY, Chen TW, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Hwang DR, Chern JH, Hwang LL, Chang JY, Chao YS, Chen CT.
    Cancer Sci; 2011 Jan 15; 102(1):182-91. PubMed ID: 21040217
    [Abstract] [Full Text] [Related]

  • 10. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY.
    J Pharmacol Exp Ther; 2007 Oct 15; 323(1):398-405. PubMed ID: 17660383
    [Abstract] [Full Text] [Related]

  • 11. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD.
    Clin Cancer Res; 2008 Oct 01; 14(19):6218-27. PubMed ID: 18829501
    [Abstract] [Full Text] [Related]

  • 12. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
    Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai NM, Chen SP, Chang WL, Harn HJ.
    Biochem Pharmacol; 2006 Jul 28; 72(3):308-19. PubMed ID: 16782069
    [Abstract] [Full Text] [Related]

  • 14. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K.
    Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285
    [Abstract] [Full Text] [Related]

  • 15. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz J, Wang LG, Perez-Soler R, Marcelli M, Bekesi G, Holland JF.
    Cancer Res; 2002 Nov 01; 62(21):6080-8. PubMed ID: 12414632
    [Abstract] [Full Text] [Related]

  • 16. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu FF.
    Clin Cancer Res; 2006 Sep 15; 12(18):5557-69. PubMed ID: 17000693
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, structure elucidation and identification of antitumoural properties of novel fused 1,2,4-triazine aryl derivatives.
    Sztanke K, Pasternak K, Rzymowska J, Sztanke M, Kandefer-Szerszeń M.
    Eur J Med Chem; 2008 May 15; 43(5):1085-94. PubMed ID: 17868955
    [Abstract] [Full Text] [Related]

  • 18. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
    Kupchinsky S, Centioni S, Howard T, Trzupek J, Roller S, Carnahan V, Townes H, Purnell B, Price C, Handl H, Summerville K, Johnson K, Toth J, Hudson S, Kiakos K, Hartley JA, Lee M.
    Bioorg Med Chem; 2004 Dec 01; 12(23):6221-36. PubMed ID: 15519165
    [Abstract] [Full Text] [Related]

  • 19. Identification and characterization of A-105972, an antineoplastic agent.
    Wu-Wong JR, Alder JD, Alder L, Burns DJ, Han EK, Credo B, Tahir SK, Dayton BD, Ewing PJ, Chiou WJ.
    Cancer Res; 2001 Feb 15; 61(4):1486-92. PubMed ID: 11245455
    [Abstract] [Full Text] [Related]

  • 20. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
    Wang X, Yuan S, Wang J, Lin P, Liu G, Lu Y, Zhang J, Wang W, Wei Y.
    Toxicol Appl Pharmacol; 2006 Sep 01; 215(2):168-78. PubMed ID: 16563451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.